Physician profile
Swathi Talla
NPI 1295224095
$5,505.05
in general payments reported to CMS, 2019-2025
29 companies · $2,595 in 2025
The $2,595 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $51.81 · 2022: $12.04 · 2023: $719 · 2024: $2,127 · 2025: $2,595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,441.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $806.91 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $724.85 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $719.52 | 2023-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $579.92 | 2023-2025 | Ubrelvy |
| Axsome Therapeutics, INC. | $517.26 | 2024-2025 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $426.40 | 2023-2025 | |
| Lilly USA, LLC | $374.26 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $160.44 | 2024-2025 | |
| Exact Sciences Corporation | $154.85 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $115.16 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $110.04 | 2023-2024 | Trintellix |
| Idorsia Pharmaceuticals US INC | $102.01 | 2023-2024 | Quviviq |
| Paratek Pharmaceuticals, INC. | $86.77 | 2024-2025 | Nuzyra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.35 | 2023-2025 | Xifaxan, Trulance |
| Esperion Therapeutics, INC. | $69.75 | 2023-2025 | Nexletol |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.98 | 2023-2024 | Synjardy, Jardiance |
| Merck Sharp & Dohme LLC | $57.76 | 2023 | Verquvo, Belsomra |
| Tolmar, INC. | $49.75 | 2024-2025 | Jatenzo |
| Janssen Biotech, INC. | $47.12 | 2025 | Tremfya |
| Otsuka America Pharmaceutical, INC. | $43.58 | 2024-2025 | Rexulti |
| Dexcom, INC. | $42.59 | 2023-2024 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $41.21 | 2024 | Veozah |
| Currax Pharmaceuticals LLC | $29.83 | 2025 | Contrave |
| Viatris Specialty LLC | $23.56 | 2025 | Yupelri |
| Janssen Pharmaceuticals, INC | $21.76 | 2021 | |
| Medtronic, INC. | $19.23 | 2023 | Intellis Adaptivestim |
| Lundbeck LLC | $16.08 | 2024 | Rexulti |
| Phathom Pharmaceuticals, INC. | $15.48 | 2025 | Voquezna |
| Glaxosmithkline, LLC. | $14.63 | 2024 | Arexvy, Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Swathi Talla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.